Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Mesothelin (MSLN) is overexpressed by many cancers, including pancreatic ductal adenocarcinoma (PDAC) and has consequently become a target for anti-cancer therapeutics. Mature, membrane bound MSLN is cleaved by proteases, releasing a shed form that transits to the circulation. Many patients with mes...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xianyu, Yu, Yunkai, Peer, Cody J., Landsman, Rebekah, Skorupan, Nebojsa, Cao, Liang, Alewine, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079715/
https://www.ncbi.nlm.nih.gov/pubmed/35523008
http://dx.doi.org/10.1016/j.tranon.2022.101440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079715/
https://www.ncbi.nlm.nih.gov/pubmed/35523008
http://dx.doi.org/10.1016/j.tranon.2022.101440

Ejemplares similares